Historically, it has been challenging to mobilize drug development and research within the rare disease sphere. Given the smaller community sizes, as well as a general lack of profitability,…
According to a story from Healio, a phase 3 clinical trial evaluating pembrolizumab plus perioperative chemotherapy as a treatment for locally advanced and resectable gastric adenocarcinoma and gastroesophageal junction cancer…
In a video conversation on OncLive, Dr. Daniel Catenacci and Dr. Sam Klempner discuss new biomarkers and therapeutic agents that could have implications for the future treatment of gastric cancer…
According to a story from Pharma Times, the drug company Bristol Myers Squibb has recently announced that its therapy nivolumab (marketed as Opdivo) has been approved by the European Commission…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
